Earnings Roundup.

* Cubist Pharmaceuticals Inc., of Lexington, Mass., said U.S. sales of Cubicin (daptomycin) increased 12 percent to $154.5 million for the third quarter, while the firm's net product revenues from international sales were $6 million. Total net revenues were $162.1 million, below analyst estimates of $167.6 million. But …